-
-
-
-
-
Stem Cell Therapy: 5 Major Challenges
Biotech
Explore the five major challenges in stem cell therapy, including sourcing, immune response, functional heterogeneity, post-transplant viability, and targeted delivery. Learn how these affect clinical outcomes.
-
BioNTech Acquires CureVac in $1.25B mRNA Deal
BioNTech
BioNTech acquires CureVac in a $1.25 billion all-stock deal, expanding its mRNA cancer therapy pipeline and resolving ongoing litigation. The acquisition strengthens BioNTech’s oncology strategy and manufacturing capabilities.
-
Bristol Myers Squibb Bets on ACP3 in $1.35B Deal
BMS
Bristol Myers Squibb teams up with Philochem in a $1.35B radiopharma deal to develop OncoACP3, a novel prostate cancer therapy targeting ACP3, offering a potential alternative to PSMA-focused treatments.
-
-
-
新昌县|
娄烦县|
松滋市|
清流县|
遵化市|
凌云县|
康保县|
松滋市|
裕民县|
安义县|
阆中市|
忻州市|
灌阳县|
历史|
万年县|
宁强县|
江阴市|
蕉岭县|
离岛区|
无锡市|
广州市|
梁河县|
门头沟区|
昌乐县|
盈江县|
灵武市|
奈曼旗|
潜山县|
黄梅县|
罗定市|
永仁县|
酒泉市|
东光县|
牙克石市|
桐庐县|
广饶县|
沅江市|
宜宾市|
富源县|
图木舒克市|
定远县|